Crossmark

Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study

Crossref DOI link: https://doi.org/10.1007/s12325-020-01350-w

Published Online: 2020-05-12

Published Print: 2020-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kabadi, Shaum M.

Near, Aimee

Wada, Keiko

Burudpakdee, Chakkarin
Funding

Funding for this research was provided by:

AstraZeneca
License Information

Text and Data Mining valid from 2020-05-12

Version of Record valid from 2020-05-12
More Information

Article History

Received: 3 March 2020

First Online: 12 May 2020

Change Date: 13 June 2020

Change Type: Correction

Change Details: In the original article, it has been noticed that the abbreviation ‘‘CLL’’ is incorrectly published throughout the paper as the abbreviation “CCL”. The correct abbreviation is “CLL”.

Updates are available Correction dated 2020-06-13

Click to view Correction: https://doi.org/10.1007/s12325-020-01400-3